Elamipretide for Health & Longevity

Evidence Review created on 10/24/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: SS-31, MTP-131, Bendavia, Forzinity, Elamipretide Hydrochloride

Motivation

Elamipretide, also known as SS-31, is a small laboratory-made chain of four amino acids that is injected under the skin and travels into mitochondria, the structures that produce most of a cell’s energy. Inside them it attaches to a fat molecule that holds the energy-making machinery in shape, a structure that tends to wear down with age. Because falling cellular energy output is regarded as one process behind aging, the compound has attracted interest as a way to restore energy in older muscle and heart.

Scientists in New York came across this family of molecules by chance in the early 2000s, and a single company then carried elamipretide through human testing in heart disease, inherited muscle disorders and age-related vision loss. In 2025 United States regulators gave it conditional approval for a rare inherited heart and muscle disorder called Barth syndrome, and studies in elderly mice have drawn the attention of people pursuing longer, healthier lives.

This review examines the human and animal evidence on elamipretide’s benefits and harms for health-focused adults, how it is dosed and monitored, and how far findings from rare diseases and old mice carry over to healthy people.

Benefits - Risks - Protocol - Conclusion

This section lists overview articles, expert commentary and key papers that discuss elamipretide by name.

Content from Rhonda Patrick, Andrew Huberman, Chris Kresser and Life Extension Magazine is not listed: web searches and each platform’s own search returned no material discussing elamipretide or SS-31.

Grokipedia

Elamipretide

AI-written encyclopedia entry covering the drug’s development history, the 2025 Barth syndrome approval, its cardiolipin-binding mechanism and other trials; useful as orientation, though it gives favorable framing more weight than the negative trials.

Examine

No Examine article on elamipretide exists. Examine.com does not typically cover prescription medications, and elamipretide is a prescription drug.

ConsumerLab

No ConsumerLab article on elamipretide exists. ConsumerLab does not typically cover prescription medications; the term appears only inside a members-only review of other energy-related supplements.

Systematic Reviews

These systematic reviews and meta-analyses (statistical pooling of trial results) pool elamipretide trials together with trials of other mitochondria-targeted agents.

Mason et al. covers both the claimed effects and the principal risk (injection-site reactions); no review addresses elamipretide alone or its use in healthy adults.

Mechanism of Action

Elamipretide is a four-amino-acid peptide (D-arginine, dimethyltyrosine, lysine, phenylalanine amide) whose alternating aromatic and positively charged residues let it cross cell membranes and concentrate in the inner mitochondrial membrane (Szeto & Birk, 2014), a lead explanation advanced largely by the discoverer and the manufacturer, Stealth BioTherapeutics.

  • Cardiolipin binding: It binds cardiolipin, which holds together the electron transport chain (the protein series that turns food-derived electrons into ATP) and the folded inner membrane; binding is proposed to stabilize this structure and improve energy output (Sabbah et al., 2025).
  • Energy transport: In old mouse muscle it raised ADP (adenosine diphosphate, ATP’s spent form) uptake through ANT (adenine nucleotide translocator, the carrier importing ADP), restoring ATP production (Pharaoh et al., 2023).
  • Competing explanations: It was first described as an antioxidant that lowers ROS (reactive oxygen species, damaging oxygen by-products) (Zhao et al., 2004); later work suggests it mainly alters membrane surface charge (Mitchell et al., 2020) or binds many proteins (Chavez et al., 2020). Effects appear only in impaired mitochondria; young muscle did not respond (Siegel et al., 2013).
  • Pharmacology: After subcutaneous (under-the-skin) injection, about 92% is absorbed and levels peak in 0.5–1 hour; it spreads through body water, is 39% protein-bound, avoids CYP (cytochrome P450, the liver’s main drug-processing enzymes) metabolism, is broken into inactive fragments and is excreted in urine within 48 hours (FDA label). Half-life is short: plasma levels were undetectable 24 hours after an infusion (Daubert et al., 2017).

Historical Context & Evolution

  • Original intended use: Hazel Szeto and Peter Schiller described the “SS” peptides in the early 2000s as cell-permeable antioxidants to limit reperfusion injury (damage when blood flow returns to oxygen-starved tissue) (Zhao et al., 2004); the discovery was by chance (Szeto & Birk, 2014).
  • Cardiovascular trials: Stealth BioTherapeutics funded heart-attack and heart-failure trials; a heart-attack trial found no reduction in heart damage (Gibson et al., 2016) and a 4-week heart-failure trial no change in heart size (Butler et al., 2020).
  • Rare mitochondrial disease: A short trial suggested better walking in inherited mitochondrial muscle disease, but the 218-person phase 3 (large confirmatory) trial found no difference (Karaa et al., 2023). In Barth syndrome, a placebo-controlled phase missed its goals while long open-label (unblinded, uncontrolled) use showed gains (Thompson et al., 2024), leading to accelerated approval in September 2025 (FDA).
  • Path to longevity interest: University of Washington groups showed that one dose restored energy production and muscle fatigue resistance, and eight days raised endurance, in old mice (Siegel et al., 2013) and that eight weeks reversed age-related heart stiffening (Chiao et al., 2020).
  • How opinion shifted: The antioxidant model gave way to cardiolipin and membrane-charge models, and null trials in common heart disease narrowed hopes toward rare disease and eye disease. None of this settles whether healthy aging people benefit.

Expected Benefits

Nearly all human trials were sponsored by the manufacturer, Stealth BioTherapeutics, and none enrolled healthy middle-aged adults using the drug for prevention.

High 🟩 🟩 🟩

No benefit reaches High: no clinical endpoint has been replicated in randomized trials from independent research groups, and the largest randomized trials in muscle disease, heart failure and heart attack found no effect.

Medium 🟩 🟩

No benefit reaches Medium: each positive human finding comes from an uncontrolled extension, a post hoc (after-the-fact) subgroup or a small pilot, and the matching larger randomized trial was null or untested.

Low 🟩

Muscle Energy Capacity and Fatigue in Older Adults ⚠️ Conflicted

In 39 adults aged 60–85, one infusion briefly raised maximal ATP production, but fatigue resistance did not improve and the effect was gone by day 7 (Roshanravan et al., 2021). Old mice became less frail (Mitchell et al., 2025). Net: a brief biochemical signal without human functional benefit.

Magnitude: Mean maximal ATP production rate rose 0.17 vs 0.12 mM/s with placebo (NCT02245620 registry results; between-group P = 0.055, the probability of a chance finding; no CI (confidence interval, the range likely to hold the true value) reported); fatigue resistance did not differ between groups.

Muscle Function and Walking in Inherited Mitochondrial Disease ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Bears on inherited mitochondrial muscle disease and Barth syndrome, not healthy aging. Short trials suggested longer walks (Karaa et al., 2020), but 24 weeks in 218 patients did not (Karaa et al., 2023). Barth patients gained only in open-label extension (Thompson et al., 2024). Net: randomized evidence is null.

Magnitude: 6-minute walk distance (meters walked in six minutes) −3.2 m vs placebo (95% CI −18.7 to 12.3) at 24 weeks in myopathy (muscle disease); Barth knee-extensor strength median +4 vs −5 newtons with placebo at week 12, not compared between groups (descriptive, FDA label), and +63 newtons at week 168 (no control group).

Heart Function ⚠️ Conflicted

In heart failure with reduced ejection fraction (a weakened, enlarged heart), an infusion briefly shrank heart volumes (Daubert et al., 2017); four weeks of injections in 71 patients did not (Butler et al., 2020). Old mice regained diastolic (filling) function (Chiao et al., 2020). Net: no lasting human benefit.

Magnitude: Left ventricular end-systolic volume (blood left in the main pumping chamber after each beat) change +2.3 mL vs placebo with 40 mg daily (95% CI −1.9 to 6.5); single infusion −14 mL vs placebo at infusion end (no CI reported).

Heart Muscle Protection During Heart-Attack Treatment ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Bears on heart-attack treatment, not healthy aging. Animals showed less damage when blood flow returned to blocked heart muscle (Zhao et al., 2004); in a randomized trial, a 1-hour infusion during stenting did not reduce infarct size (dead heart muscle) (Gibson et al., 2016). Net: animal benefit did not translate.

Magnitude: Infarct size by CK-MB (a heart-damage enzyme) area under the curve (total enzyme release summed over time) over 72 hours 5570 vs 5785 ng·h/mL with placebo; difference not significant and reported without a confidence interval.

Kidney Protection During Kidney-Artery Stenting ⭕️ Not Central to Health & Longevity

Bears on procedure-related kidney injury, not healthy aging. In a 14-patient randomized pilot (Saad et al., 2017), infusion lessened post-stenting kidney oxygen loss. The abstract implies a larger eGFR (estimated glomerular filtration rate, kidney filtering capacity) rise than placebo; the results report within-group tests only.

Magnitude: eGFR 40.7 to 46.5 with elamipretide vs 34.4 to 37.0 mL/min/1.73 m² with placebo over 3 months; not compared between groups.

Dry AMD (age-related macular degeneration, gradual central-vision loss) involves failing retinal mitochondria. In 176 patients, 48 weeks of injections missed both primary endpoints, while secondary measures suggested slower photoreceptor (light-sensing retinal cell) loss (Ehlers et al., 2025). Net: an unconfirmed signal now in phase 3.

Magnitude: Primary endpoints (low-light visual acuity, atrophy growth) not significant vs placebo; ≥10-letter low-light acuity gain in 14.6% vs 2.1% with placebo (nominal P = 0.04, unadjusted for multiple testing).

Speculative 🟨

Brain and Cognitive Aging

Old female mice treated 10 months scored better cognitively (Nickel et al., 2022); brain microbleeds (tiny bleeds) in old hypertensive mice did not fall (Patai et al., 2025). Basis is animal data only.

Ovarian Aging and Fertility

In aged mice, injections increased litter size and egg quality, and aged human eggs matured better in the laboratory (Zhang et al., 2026). Basis is animal and laboratory data only.

Biological Age and Lifespan

Eight weeks in old mice left epigenetic and gene-expression aging clocks unchanged (Mitchell et al., 2025), and no published study has tested lifespan. Basis is mechanistic and animal data only.

Benefit-Modifying Factors

  • Genetic subtype: Post hoc, patients with POLG or TWNK variants (genes for enzymes copying mitochondrial DNA) trended toward walking farther (p = 0.06); those with mitochondrial DNA variants did not (Karaa et al., 2024). No genetic marker predicts response in healthy people.
  • Baseline biomarkers: Benefits track existing impairment: old but not young mouse muscle responded (Siegel et al., 2013), and walking gains were largest with the shortest baseline walk (Karaa et al., 2018). No routine blood test predicts response.
  • Sex: In old mice, males gained physical performance and females gained cognition and body-weight maintenance (Nickel et al., 2022). Human trials report no sex-specific effects; Barth data are male-only.
  • Pre-existing conditions: Signals appear in disorders of cardiolipin or mitochondrial DNA upkeep, while trials in common heart failure and heart attack were null (Butler et al., 2020). Adults with healthy mitochondria may have little to restore.
  • Age: Human aging data come from one single-dose trial in 60–85-year-olds (Roshanravan et al., 2021); Barth trials enrolled no one over 65 (FDA label). The oldest adults, with the most mitochondrial decline, are least studied.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Injection-Site Reactions

Redness, itching, pain, hardening, bruising and hives at the injection site are the most common adverse events of daily subcutaneous use, reported in trials led by Karaa et al. (2023), Ehlers et al. (2025) and Thompson et al. (Barth syndrome; 2024; FDA label), and confirmed by meta-analysis (Mason et al., 2022). Most are mild to moderate, but they are the main reason people stop: in older adults with macular degeneration, 17.1% stopped treatment because of them (the placebo rate for this reason is not reported).

Magnitude: Injection-site events 60% vs 27% with placebo (ReCLAIM-2, mean age 76); any local reaction 100% vs 67% (Barth crossover, n = 12); discontinuation for adverse events 7.3% vs 1.8% with placebo (MMPOWER-3).

Medium 🟥 🟥

Eosinophil Elevation

Eosinophils (allergy-related white blood cells) rose in 6.0% of treated patients vs none on placebo in one 48-week trial (Ehlers et al., 2025). The label notes frequent rises with use beyond 30 days, peaking near day 90 and normalizing within 6–12 months or after stopping, without symptoms. Evidence comes from a single controlled trial plus label description.

Magnitude: Eosinophil count increase 6.0% vs 0% with placebo (ReCLAIM-2); mean rise about 0.5–0.6 × 10³/µL at peak (no control group) (FDA label).

Low 🟥

Hypersensitivity Reactions ⚠️ Conflicted

The label reports allergic reactions, some needing emergency care, with rash, papular (raised-bump) or eczema-like lesions and cough, from minutes to months after starting (FDA label). Pooled randomized trials found no serious treatment-emergent events (Mason et al., 2022). Net: rare but documented.

Magnitude: Not quantified in available studies. The label gives no incidence, and the pooled randomized trials recorded no serious cases to count.

Benzyl Alcohol Toxicity in Neonates

The product’s benzyl alcohol preservative (20 mg/mL) can cause gasping syndrome (a potentially fatal build-up of acid in the blood) in preterm and low-birth-weight infants given benzyl alcohol–containing drugs intravenously (Gershanik et al., 1982; FDA label). Evidence comes from case reports with other drugs, not elamipretide itself.

Magnitude: Not quantified in available studies. Only case reports exist, and the label states that the benzyl alcohol amount at which toxicity may occur in neonates is not known.

Speculative 🟨

Blood-Pressure Drop at High Exposure

The label expects overdose signs to be histamine-related, such as low blood pressure and near-fainting; trial infusions kept blood pressure stable (Daubert et al., 2017). Basis is label inference only.

Unknown Long-Term and Cancer Risk

Carcinogenicity has not been studied, and the longest human exposure is 192 weeks in a few Barth patients (FDA label). Decades-long use in healthy adults is untested. Basis is absence of data.

Contaminated or Mislabeled Research Peptides

Unapproved “SS-31” sold for research has no regulatory quality control, so purity, sterility and dose may differ from labeling. No testing data specific to elamipretide products exist; the basis is mechanistic only.

Risk-Modifying Factors

  • Kidney function: Exposure rises 39%, 75% and 125% with mild, moderate and severe kidney impairment, and inactive fragments rise up to 640% when severe (FDA label). Dialysis has not been studied.
  • Baseline biomarkers: Phase 3 trials exclude eosinophil counts above 1,000 cells/µL and eGFR below 30 mL/min (ReNEW), defining who has been studied for safety.
  • Genetics: Elamipretide bypasses CYP enzymes, so common CYP gene variants are not expected to change exposure (FDA label); no other genetic risk factors are known.
  • Sex: Barth data are male-only, and the myopathy trial was 64% female with no sex-specific safety signal reported (Karaa et al., 2023). Pregnancy data are absent.
  • Pre-existing conditions: A history of systemic eosinophilic illness (disorders with excess eosinophils damaging organs), or prior allergic reaction to the drug or any component such as its benzyl alcohol preservative, raises hypersensitivity concern; trials excluded these groups (ReNEW).
  • Age: In older adults (mean age 76), injection-site events were 60% vs 27% and early withdrawal 29% vs 14% with placebo (Ehlers et al., 2025). Fragment clearance falls with age (Karaa et al., 2023).

Key Interactions & Contraindications

Human interaction studies exist only for aspirin, clopidogrel and heparin; the remaining entries rest on laboratory data or mechanism.

  • Antiplatelet drugs (platelet-clumping blockers: aspirin, clopidogrel): A human interaction study found no change in aspirin or clopidogrel levels or antiplatelet effect (FDA label); no bleeding-risk increase is expected.
  • Anticoagulants (blood thinners: unfractionated heparin): Co-infusion did not alter clotting measures or heparin activity in a human study (FDA label); no dose change is indicated.
  • CYP-metabolized drugs (atorvastatin, warfarin, sertraline): Elamipretide neither inhibits nor induces major CYP enzymes in laboratory tests (FDA label), so altered levels of these drugs are not expected.
  • MATE1 substrates (metformin) (theoretical): Elamipretide blocks MATE1 (a kidney drug-export pump) in laboratory tests (FDA label); metformin levels could rise, raising the chance of gastrointestinal adverse effects.
  • Kidney-stressing drugs (ibuprofen, naproxen, gentamicin) (theoretical): Lower kidney function raises elamipretide exposure (FDA label); regular use could increase levels; periodic eGFR checks detect this.
  • Antihistamines and topical corticosteroids (anti-inflammatory steroid creams) (cetirizine, fexofenadine, hydrocortisone cream): The label recommends these for mild skin reactions (FDA label); no interaction is reported.
  • Mitochondrial supplements (NMN, coenzyme Q10, creatine) (theoretical): In old mice, elamipretide plus NMN (nicotinamide mononucleotide, a precursor of the cellular energy carrier NAD) raised resting NAD more than either alone (Whitson et al., 2020); additive effects are possible, human safety unknown.
  • Other injectable peptides (semaglutide, insulin) (theoretical): Mixing in one syringe is prohibited by the label (FDA label); combined injection-site irritation is possible, which separate syringes and sites avoid.

Populations who should avoid Elamipretide:

  • Prior serious hypersensitivity to elamipretide or any ingredient, including benzyl alcohol: absolute contraindication (FDA label)
  • Neonates, because of benzyl alcohol toxicity: Avoid (FDA label)
  • eGFR below 30 mL/min on dialysis, for which no dosing data exist (FDA label)
  • Eosinophil count above 1,000 cells/µL or a history of systemic eosinophilic illness (trial exclusion, ReNEW)
  • Pregnancy or breastfeeding, for which human data are absent (trial exclusion, ReNEW)
  • Active cancer or cancer-free for less than 2 years, since carcinogenicity is unstudied (trial exclusion, ReNEW)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Injection-site rotation: The label specifies the abdomen at least 2 inches from the navel or the outer thigh, rotated daily, avoiding tender, bruised or scarred skin (FDA label); this reduces local reactions.
  • Early treatment of skin reactions: Topical corticosteroids and oral antihistamines are labeled for mild reactions, and the label advises considering discontinuation if reactions persist or worsen (FDA label). This limits injection-site and allergic escalation.
  • Stop rule for serious allergy: After a serious hypersensitivity reaction, the label calls for permanent discontinuation without re-challenge; epinephrine and emergency care treat the reaction (FDA label). This prevents repeat anaphylaxis (severe whole-body allergy).
  • Kidney-based dosing: eGFR is checked before starting; below 30 mL/min without dialysis the labeled dose is 20 mg daily (FDA label). This prevents drug and fragment accumulation.
  • Eosinophil tracking: A blood count with differential (white-cell breakdown) at baseline and around 3 months, when rises peak (FDA label), catches eosinophil elevation, the drug’s main laboratory effect.
  • Pharmaceutical-grade product: The approved product, unlike research-grade “SS-31”, avoids contamination, wrong dosing and non-sterile vials.
  • Vial hygiene: The label calls for aseptic technique, a new syringe each time, and discarding opened vials after 8 days (FDA label); this prevents injection infections.
  • Subcutaneous route only: The product is approved only for subcutaneous injection, not intravenous use, and contains benzyl alcohol, which caused fatal toxicity in neonates given it intravenously (FDA label); this avoids untested routes.

Therapeutic Protocol

Other parameters below without a citation (timing, cycling, titration) reflect common practice.

  • Labeled regimen: 40 mg subcutaneously once daily at the same time each day; a missed dose is skipped, not doubled (FDA label). Popularized by Stealth BioTherapeutics’ trial program.
  • Trial regimens: 40 mg daily in myopathy and eye trials (Karaa et al., 2023; Ehlers et al., 2025); 4 or 40 mg daily in heart failure (Butler et al., 2020); one 2-hour infusion in older adults (Roshanravan et al., 2021).
  • Intermittent alternative: The Marcinek laboratory gave old mice injections twice weekly for 8 months, preserving exercise tolerance but not kidney benefits seen with continuous dosing (Campbell et al., 2023); no human data.
  • Off-label self-dosing: Peptide-community self-reports, summarized by Grokipedia, describe 0.5–4 mg daily, 4 mg five days on and two off, or 20 mg twice weekly of research-grade “SS-31”; no trial has tested these doses.
  • Short course in older adults: The same group is testing 4 weeks of daily injections in 65–80-year-olds (SHAPE); the registry does not state the dose.
  • Time of day: No study compares times; consistent daily timing follows the label, and morning dosing lets injection-site reactions be watched while awake.
  • Half-life: Levels peak 0.5–1 hour after injection (FDA label) and vanish within 24 hours (Daubert et al., 2017); muscle effects faded by day 7 (Roshanravan et al., 2021), supporting daily use.
  • Single vs split dose: The label specifies one daily injection (FDA label); split dosing has not been studied.
  • Genetic factors: No pharmacogenetic dose rules exist; variants in mitochondrial DNA upkeep genes showed a trend toward response in myopathy, without dose changes (Karaa et al., 2024).
  • Sex: Dosing is fixed for anyone weighing at least 30 kg, with no sex adjustment (FDA label); mouse responses differed by sex (Nickel et al., 2022).
  • Age: The label has no geriatric adjustment, but kidney decline with age can trigger the 20 mg dose (FDA label); older adults tolerated 40 mg daily for 48 weeks (Ehlers et al., 2025).
  • Baseline biomarkers: eGFR sets the dose; lower baseline walking distance predicted larger gains in myopathy (Karaa et al., 2018).
  • Pre-existing conditions: Severe kidney impairment halves the dose (FDA label); heart failure patients received 40 mg daily without dose-limiting problems (Butler et al., 2020).

Discontinuation & Cycling

  • Duration: Barth syndrome use is long-term, up to 192 weeks in trials (FDA label); effects reverse quickly, fading within 2–7 days of stopping (Roshanravan et al., 2021; Karaa et al., 2018).
  • Withdrawal effects: None reported; eosinophil counts return to baseline after stopping (FDA label).
  • Tapering: Not required; trials stopped abruptly, including a 4-week washout between crossover periods (Reid Thompson et al., 2021).
  • Cycling: No human data; twice-weekly dosing in old mice kept part of the benefit of continuous dosing (Campbell et al., 2023).

Sourcing and Quality

  • Approved product: Forzinity (Stealth BioTherapeutics) comes as 280 mg/3.5 mL vials (80 mg/mL) with benzyl alcohol preservative, by prescription only (FDA label); it is the only product with regulator-verified quality.
  • Compounded versions: Some compounding pharmacies prepare elamipretide; these are not FDA-approved products (FDA). Pharmacy accreditation and batch certificates of analysis for identity, potency, sterility and endotoxin (bacterial toxin) indicate quality.
  • Research-grade peptides: “SS-31” sold for research has no quality oversight; independent HPLC (high-performance liquid chromatography, a purity test) and mass-spectrometry (molecular-weight identity test) reports are the minimum check.
  • Formulation: Only the subcutaneous form is approved (FDA label); the peptide is not absorbed when swallowed (Campbell et al., 2023), so oral or nasal products lack supporting data.
  • Storage: Refrigerate unopened vials at 2–8 °C without freezing; opened vials keep refrigerated or at room temperature for 8 days (FDA label).

Practical Considerations

  • Time to effect: Muscle energy changes appear within hours (Roshanravan et al., 2021); strength gains in Barth syndrome emerged over 12–24 weeks of open-label use (FDA label). No time course exists for healthy adults.
  • Common pitfalls: Treating rare-disease approval as proof of healthy-aging benefit, skipping site rotation, buying unverified research peptides, and expecting a drop in epigenetic age, which old mice did not show (Mitchell et al., 2025).
  • Regulatory status: FDA accelerated approval (September 19, 2025) covers only Barth syndrome in patients weighing at least 30 kg, pending a confirmatory trial (FDA); longevity use is off-label.
  • Cost and access: Cash price is about $59,636 per 14 mL, a 28-day supply (Drugs.com); insurance coverage outside Barth syndrome is unlikely.
  • Payer incentives: At this price, insurers and health systems have a financial incentive to limit coverage to the label, while low-cost options such as exercise training face no such pressure, a structural factor shaping access and research funding.
  • Daily injections: Use requires daily self-injection after training, refrigeration and sharps disposal (FDA label), a lasting burden.

Interaction with Foundational Habits

  • Sleep: No direct interaction reported (none); trials list no sleep disturbance. Indirectly, itching from injection-site reactions could disturb sleep, so morning injections and site rotation are practical choices.
  • Nutrition: No nutrient depletion known (none). In old mice, a high-fat, high-sugar diet worsened heart and muscle measures with or without treatment (Nickel et al., 2022); diet quality remains independent. NMN may potentiate effects in mice (Whitson et al., 2020).
  • Exercise: Likely overlapping (indirect): both target muscle mitochondria, and the drug acts mainly where mitochondria are impaired (Siegel et al., 2013), so trained people may gain less. The older-adult trial excludes regular exercisers (SHAPE); timing relative to workouts is unstudied.
  • Stress management: No interaction expected (none); no study has measured cortisol or stress responses. Mechanistically, reduced oxidative stress is cellular, not psychological, so no blunting of stress-management practices is expected.

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes kidney function, which sets the dose, and an eosinophil count, which the drug can raise (FDA label). Because no blood marker tracks benefit, baseline function tests such as a timed walk and leg-strength measurement provide the reference against which any change is judged, repeated under the same conditions each time.

Ongoing monitoring follows this cadence: a blood count at 4 weeks and 3 months, when eosinophil rises peak; eGFR at 3 months, then every 6–12 months; and repeat function tests at 3 and 6 months. Injection sites and any rash or cough are checked daily during the first months, because allergic reactions can appear from minutes to months after starting. Success means measurable improvement in walking or strength over one’s own baseline without safety signals; no change after 3–6 months suggests no benefit.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
eGFR (estimated glomerular filtration rate) ≥60 mL/min/1.73 m² (standard reference range) Safety check: sets the dose Track change from own baseline; below 30 mL/min/1.73 m² the labeled dose halves (FDA label); creatinine-based, no fasting needed
Absolute eosinophil count 0.0–0.5 × 10³/µL (standard reference range) Safety check: the drug raises it Part of a complete blood count with differential (white-cell breakdown); rises peak near day 90 (FDA label); trials exclude counts above 1.0 × 10³/µL (ReNEW)
6-minute walk distance No established target; track change from own baseline Expected to change: main trial endpoint Same course, time of day and instructions each test (Karaa et al., 2023)
Knee-extensor strength (handheld dynamometer, a force gauge) No established target; track change from own baseline Expected to change: basis of approval Measured in newtons; pair with walk test (FDA label)

Qualitative markers to track:

  • Injection-site condition (redness, itching, hardening, bruising)
  • New rash, hives or cough suggesting allergy
  • Fatigue during everyday activities
  • Exercise tolerance, such as stair climbing or walking pace
  • Recovery after physical exertion

Emerging Research

  • Older-adult safety trial (SHAPE): Open-label phase 2a study of 4 weeks of daily injections in 30 adults aged 65–80 with low fitness (NCT07275424). Registered completion (April 2026) has passed; the registry still lists recruiting, with no results. Positive: justifies a placebo-controlled healthy-aging trial; null: weakens the prevention case.
  • Phase 3 in dry macular degeneration (ReNEW): 313 participants, 40 mg daily for 96 weeks, primary endpoint photoreceptor loss at week 48 (NCT06373731); completion expected September 2027. Positive: first replicated benefit in a common age-related disease; null: removes the strongest age-related human signal.
  • Barth confirmatory trial (4TAZPower): Randomized, placebo-controlled, 48 males, 72 weeks, composite walking and sit-to-stand endpoint (NCT07531251); completion expected November 2029. Positive would confirm the approved benefit; null would undermine the only regulatory approval.
  • Nuclear-DNA mitochondrial disease (NuPOWER): Phase 3, 102 participants, 48 weeks (NCT05162768); completed December 2024 without registry results; the sponsor presented overall outcomes and a possible POLG1-subgroup response at Euromit 2026, without public figures (Stealth). Positive results would support genotype-guided benefit; null results would close the main myopathy avenue.
  • Function without younger clocks: Old mice improved without epigenetic age change (Mitchell et al., 2025), so human aging trials need functional endpoints; clock-based marketing claims lack support.
  • Mechanism and responder markers: Membrane-charge (Mitchell et al., 2020) and ADP-transport findings (Pharaoh et al., 2023) may yield biomarkers that identify who has impaired mitochondria worth treating.
  • Pooled evidence that could cut either way: The low-certainty heart-failure meta-analysis (Mohammed et al., 2026) and the null metabolic meta-analysis (Mason et al., 2022) show how much rests on small trials; larger independent trials could reverse current readings in either direction.

Conclusion

Elamipretide is a small injected protein fragment that enters mitochondria, the energy-producing parts of cells, and attaches to a membrane fat that keeps their energy machinery in shape. It is now an approved drug for one rare inherited disorder, and that approval rests on strength gains seen during long-term use without a comparison group rather than on a better result than placebo.

For people pursuing longer, healthier lives, the picture is mostly one of promise in animals that has not yet carried over to people. In old mice, the drug repeatedly restored muscle energy, endurance and heart function, though it did not make their cells look biologically younger. In older humans, a single dose briefly boosted muscle energy production without making muscles less tired. Larger placebo-controlled trials in inherited muscle disease, heart failure and heart attack found no benefit, and an eye-disease trial missed its main goals while hinting at slower damage.

On the risk side, the drug appears safe over months to a few years, but daily injections commonly cause redness, itching and swelling, which lead some people to stop. Some develop raised allergy-related blood cells, and rare serious allergic reactions have been reported. Effects of use over decades are unknown.

The evidence base is small and comes almost entirely from studies paid for by the company that sells the drug. Whether healthy older adults gain anything meaningful remains an open question that current human data cannot answer.

Top - Benefits - Risks - Protocol